

TABLE OF CONTENTS

August 7, 2006

No. 2003

BUSINESS

- 1 e-Trial Proposes Multinational Trials Including China
 - Clinical Data from China Will Withstand Reviews in Advanced Countries
 - Effective Use of EDC Is Key
- 2 Santen Aims for Global Business Development in FY2006-2010 Management Plan
- 4 Meiji Seika Licenses Non-steroidal Compounds to US Company
- 4 Eisai, Solvay Announce License Agreement for SA-001
- 4 New Laws Shorten "Drug Lag" in China: Mr Kosaku of CMIC
- 4 Wholesalers Have Not Yet Offered Rock-Bottom Prices
 - Former JPA Vice President to Serve NPhA as Councilor
- 5 Price Agreement Rate Exceeded 50% in 1st Qtr: Suzuken

GENERIC

- 6 Nippon Chemiphar Aims for ¥10 Bil. in GE Drug Sales in FY2006
 - Report on Uralyt-Zyloric Combination Expected Next Summer
- 6 Rate of Generic Drug Substitution Still Low: ASTEM
- 7 **GENERIC NEWS IN BRIEF**
 - Taisho Pharm. to Build New Capsule Production Facility
 - Sandoz, Momenta to Collaborate to Develop Generics

MEDICAL DEVICES

- 7 **MEDICAL DEVICE NEWS IN BRIEF**
 - Olympus Biomaterial Launches Artificial Bone Replacement
 - Astellas' Gelpart to Be Reimbursed: *Chuikyo*
 - New Mobile Phones Should Be Kept 22 cm or More from Pacemakers

REGULATORY

- 8 Approval of 32 Products Released
 - PATANOL, VEGAMOX Ophthalmic Solutions: Alcon Japan
 - Genotropin for Adult Growth Hormone Deficiency: Pfizer
 - Gabapen Tablets: Pfizer
 - Itrazole Oral Solution 1%: Janssen Pharm.
 - Fosamac Tab 35 mg: Banyu
 - Bonalon Tab 35 mg: Teijin
 - Pulmicort Respules 0.25 mg, 0.5 mg: AstraZeneca
 - Hepatitis B Treatment Baraclude Tab 0.5 mg: Bristol
- 9 All-case Studies Increasingly a Condition for Approval: OPIR
- 10 Early Approval of 4 Drugs Recommended: Council
 - 3 More Unapproved Drugs to Be Reviewed
- 10 *Chuikyo* Listens to FPMAJ, PhRMA, EFPIA on Drug Pricing
 - Discussing Only Frequency of Price Revision Is Unacceptable: FPMAJ

- Prices to Drop 40-50% during Patent Life if They Are Revised Once a Year: Mr Crenshaw
- More Frequent Price Revisions Will Make Japan Less Attractive: Mr Ohhashi
- 11 JMA Opposed to More Frequent NHI Price Revision
- 11 Council Recommends Promotion of Clinical Research
- 12 **Commentary**
 - Predicting Discussions on Bulk Buying at *Ryukaikon*
- 13 **REGULATORY NEWS IN BRIEF**
 - PMDA Calls For Registration with Safety Information e-Mailing Service
 - Fulminant Hepatitis, Hepatitis Added as Clinically Significant ADR for Atorvastatin
 - Nexavar Approved for Advanced Kidney Cancer in EU: Bayer
 - SYMBICORT Approved for Asthma in the US: AstraZeneca
 - Xeloda Filed in Europe for Advanced Stomach Cancer: Roche
 - Antibody Formation due to Factor VIII Preparations Reported

R&D

- 14 DSP, BMKK Enter Agreements for Hypertension, Cancer Treatments
- 15 24 Products Currently in Vaccine Pipeline: GSK
- 15 Wyeth Focuses on Developing 2nd-Generation Pneumococcal Vaccine
- 16 Drug Development Beyond Borders - Today's Global Cooperative Clinical Trials - Part IV: Banyu's Nulotan
- 17 28 Hospitals Participating in Shizuoka Clin. Trial Network
 - Patents to Be Applied for for 5 Compounds in 2006
- 18 **R&D NEWS IN BRIEF**
 - Long-term Efficacy, Safety of Paxil Suggested: GSK
 - Osaka Univ., Univ. of Cambridge Open MOTI Course

MEDICAL FACILITIES & NURSING CARE

- 18 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - GL on Pharmacotherapy for Bronchial Asthma in Children Published
 - Aging Society Requires "Proactive" Healthcare: JMA
 - 47 Hospitals to Be Newly Designated as Cancer Treatment Core Hospitals

SELF-MEDICATION

- 19 **SELF-MEDICATION NEWS IN BRIEF**
 - Nipro to Transfer Shares in Nissho Drug to Kirindo
 - Tonic Drink Sales to Continue to Decline in 2006: Fuji Keizai
 - Nearly 60% of People Experience Insomnia: SSP